Summary of Key Information:

Nature of Filing / Announcement: Outcome of Board Meeting - Scheme of Amalgamation

Date of Board Meeting / Approval: June 26, 2026

Meeting Time: Commenced at 11:30 a.m. and concluded at 1:00 p.m.

Key Financial Highlights:

Standalone Results:

Not Specified

Consolidated Results:

Not Specified

Company Financial Context (Disclosed for Merger):

  • Ipca Laboratories Limited (Transferee Company) Standalone Audited Total Income for FY ended 31st March 2026: Rs. 7431 Crores
  • Krebs Biochemicals & Industries Limited (Transferor Company) Audited Total Income for FY ended 31st March 2026: Rs. 26 Crores (mostly from conversion charges received from Transferee Company)

Corporate Actions:

Scheme of Amalgamation:

  • Board approved the Scheme of Amalgamation of Krebs Biochemicals & Industries Limited (Transferor Company) with Ipca Laboratories Limited (Transferee Company)
  • Approved under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013
  • Appointed Date: 1st April, 2026
  • Effective Date: Upon receipt of all consents and approvals

Consideration Structure:

  • No cash consideration payable under the Scheme
  • Share Exchange Ratio: 7 (Seven) fully paid-up equity shares of Re. 1/- each of Ipca Laboratories Limited for every 200 (Two Hundred) fully paid-up equity shares of Rs. 10/- each held in Krebs Biochemicals & Industries Limited
  • Shares held by Ipca Laboratories Limited in Krebs Biochemicals shall stand cancelled and extinguished without any consideration

Other Significant Information:

Rationale for Amalgamation:

1. Operational synergies resulting in cost optimization

2. Business consolidation resulting in increased business of the combined entity

3. Transferor company has fermentation-based API manufacturing capability which Transferee company lacks

4. Enables Transferee company to research, develop and commercialize new fermentation-based APIs

5. Secures uninterrupted supply of key API used in Transferee company's largest selling formulation

6. Secures uninterrupted supply of drug intermediates used in Transferee company's key APIs

7. Leverages Transferee company's financial strength and capabilities for R&D to optimally utilize Transferor company's manufacturing capabilities

Business Areas:

Both entities are engaged in the Manufacturing and Marketing of Pharmaceuticals

Filing Compliance:

Disclosure made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015